Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The study prematurely discontinued on October 11, 2011 due to slow enrollment. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Postmenopausal females, defined as one from the next :
1. Natural menopause ≥1 year,
2. Surgical ovariectomy,
3. Chemotherapy-induced amenorrhoea ≥ 2 years.
Patients who have had surgical treatment for histologically confirmed breast cancer that was non-metastatic at the time of the initial diagnosis.
Patients who are disease-free after 2 to 3 years of adjuvant tamoxifen treatment.
Patients whose tumour was estrogen receptor positive (ER+).
Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
You may not be if
Patients for whom Aromasin® treatment is contraindicated (see SmPC).
Metastatic breast cancer or a contra lateral tumour.
Other concomitant adjuvant endocrine therapy.
Other concomitant antineoplastic treatment.
Participation in a clinical trial with an investigational drug during the 30 days prior to enrolment in the study.
Clareo Health | Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer
